One promising strategy to restore wild-type p53, extensively explored as a potential cancer treatment, consists in targeting its antagonist, the MDM2 oncoprotein, with small molecule inhibitors [22,23,24,25,26,27,28,29]. This evidence concerns the gene TP53 and cancer.